Exelixis Inc (NAS:EXEL)
$ 35.91 0.06 (0.17%) Market Cap: 10.26 Bil Enterprise Value: 9.24 Bil PE Ratio: 23.02 PB Ratio: 4.51 GF Score: 91/100

Exelixis Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 29, 2021 / 06:40PM GMT
Release Date Price: $20.63 (+0.15%)
Jennifer M. Kim
Cantor Fitzgerald & Co., Research Division - Large Cap and Biopharma Analyst

Hi, everyone. I'm Jennifer Kim, a large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Exelixis. Exelixis is an oncology-focused biotech company with 4 commercial products, including their flagship product, cabozantinib, and a novel pipeline of cancer therapies.

Today, we're very excited to have with us the President and CEO, Michael Morrissey, to discuss the company's pipeline and the market opportunity for its products. Michael, thanks so much for taking the time today.

Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director

You bet. Great to be here. Thanks for that great intro, and happy to have some time with you today. Before I begin, I'll just remind everybody that I'll be making forward-looking statements. So please see our SEC filings for a description of the risks that we face in our business.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot